784 related articles for article (PubMed ID: 26563881)
1. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
[TBL] [Abstract][Full Text] [Related]
3. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
4. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
6. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
7. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
10. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
13. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
15. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
16. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
17. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
18. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
[TBL] [Abstract][Full Text] [Related]
19. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.
Benavides-Serrato A; Lee J; Holmes B; Landon KA; Bashir T; Jung ME; Lichtenstein A; Gera J
PLoS One; 2017; 12(4):e0176599. PubMed ID: 28453552
[TBL] [Abstract][Full Text] [Related]
20. 17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling.
Kusch A; Schmidt M; Gürgen D; Postpieszala D; Catar R; Hegner B; Davidson MM; Mahmoodzadeh S; Dragun D
PLoS One; 2015; 10(4):e0123385. PubMed ID: 25880554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
